Article Information
History
- November 6, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Brian J Ward1,2,
- Philipe Gobeil1,
- Annie Séguin1,
- Judith Atkins1,
- Iohann Boulay1,
- Pierre-Yves Charbonneau1,
- Manon Couture1,
- Marc-André D’Aoust1,
- Jiwanjeet Dhaliwall1,
- Carolyn Finkle1,
- Karen Hager1,
- Asif Mahmood1,
- Alexander Makarkov1,
- Matthew Cheng2,
- Stéphane Pillet1,
- Patricia Schimke1,
- Sylvie St-Martin1,
- Sonia Trépanier1 and
- Nathalie Landry1,*
- 1Medicago Inc., 1020 route de l’Église office 600, Québec, QC, Canada, G1V 3V9
- 2Research Institute of the McGill University Health Centre, 1001 Decarie St, Montreal, QC H4A 3J1
- ↵*Corresponding author: Nathalie Landry, 1020 Route de l’Église, Bureau 600, Québec, Qc, Canada, G1V 3V9, Tel. 418 658 93931, Fax. 418 658 6699, Landryn{at}medicago.com
Posted November 06, 2020.
Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants
